Status:
COMPLETED
Alteplase Treatment in Elderly Acute Ischaemic Stroke (AIS) Patients
Lead Sponsor:
Boehringer Ingelheim
Conditions:
Stroke
Eligibility:
All Genders
80+ years
Brief Summary
The objective of this study is to find out if Chinese Acute Ischaemic Stroke (AIS) patients older than 80 years benefit from intravenous (IV) Recombinant Tissue Plasminogen Activator (rt-PA) treatment...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Patients registered in the Zhejiang Stroke Quality Control Centre (ZSQCC) platform from Jan 2017 to Mar 2020
- \> 80 years of age
- Diagnosed with AIS at admission
- Arrived or admitted to the hospital within 4.5 hours of symptom onset
- If treated with IV rt-PA: received IV rt-PA within 4.5 hours of symptom onset
- Exclusion criteria:
- Documented Intravenous Thrombolysis (IVT) contraindication except age to IV rt-PA treatment according to the Summary of Product Characteristics (SmPC)
- Missing any one of the key data (age, gender, baseline National Institutes of Health Stroke Scale \[NIHSS\], time of symptom onset, time of hospital arrival or admission, IVT or not, time of IV rt-PA treatment)
- Received thrombolysis agents other than rt-PA (urokinase, tenecteplase, recombinant plasminogen activator, prourokinase, streptokinase)
- Received endovascular treatment
- Received IV rt-PA after 4.5 hours of symptom onset
Exclusion
Key Trial Info
Start Date :
July 18 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 14 2022
Estimated Enrollment :
3058 Patients enrolled
Trial Details
Trial ID
NCT05401149
Start Date
July 18 2022
End Date
December 14 2022
Last Update
October 17 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Boehringer Ingelheim (China) Investment Co., ltd.
Shanghai, China, 200040